Trial Profile

A Randomized, Double-blind, Controlled, Multicenter Phase III Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benmelstobart (Primary) ; Catequentinib (Primary) ; Carboplatin; Etoposide
Indications Small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms ETER701
Sponsors Chia Tai Tianqing Pharmaceutical Group

01 Oct 2024 Results (n=738) published in the Nature Medicine.
12 Sep 2023 Status changed to completed, according to Results presented at the 24th World Conference on Lung Cancer.
12 Sep 2023 Primary endpoint (Overall survival (OS)) has been met, according to Results presented at the 24th World Conference on Lung Cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com